Last reviewed · How we verify
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of 14\^C-labeled ertugliflozin in healthy male participants.
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 8 |
| Start date | Wed Oct 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Feb 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Type 2 Diabetes Mellitus
Interventions
- Unlabeled ertugliflozin for oral use
- 14^C-labeled ertugliflozin for IV use
- 14^C-labeled ertugliflozin for oral use